title: Mineralocorticoids participate in the reduced vascular reactivity of pregnant rats.
abstract: The renin-angiotensin-aldosterone (RAA) system is markedly activated in pregnancy. We evaluated if mineralocorticoid receptors (MR), a major component of the RAA system, are involved in the reduced vascular reactivity associated with pregnancy. Canrenoate (MR antagonist; 20 mg·kg(-1)·day(-1)) was administered to nonpregnant (NP) rats for 7 days and to pregnant rats from day 15 to 22 of gestation. These were killed on day 17, 19, or 22 of gestation and, for NP rats, after 7 days treatment. Constrictor responses to phenylephrine (PhE) and KCl were measured in endothelium-denuded thoracic aortic rings under the influence of modulators of potassium (activators) and calcium (blocker) channels. Responses to the constrictors were blunted from days 17 to 22 of gestation. Although canrenoate increased responses to PhE and KCl, it did not reverse their blunted responses in gestation. NS-1619 and cromakalim (respectively, high-conductance calcium-activated potassium channels and ATP-sensitive potassium channel activators) diminished responses to both PhE and KCl. Inhibition by NS-1619 on responses to both agonists was decreased under canrenoate treatment in NP, but the reduced influence of NS-1619 during gestation was reversed by the mineralocorticoid antagonist. Cromakalim reduced the response to PhE significantly in the pregnant groups; this effect was enhanced by canrenoate. Finally, nifedipine (calcium channel blocker) markedly reduced KCl responses but to a lesser extent at the end of pregnancy, an inhibiting effect that was increased with canrenoate treatment. These data demonstrate that treating rats with a MR antagonist increased vascular reactivity but that it differentially affected potassium and calcium channel activity in aortas of NP and pregnant animals. This suggests that aldosterone is one of the components involved in vascular adaptations to pregnancy.
authors.affiliation: Research Centre, CHU Sainte-Justine and Departments of Obstetrics-Gynecology, Université de Montréal, Montréal, Québec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Provencher
authors.forename: V
authors.initials: V
authors.lastname: Houde
authors.forename: M
authors.initials: M
authors.lastname: Brochu
authors.forename: J
authors.initials: J
authors.lastname: St-Louis
mesh_terms: D000450:Aldosterone / Q000494:pharmacology; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000502:physiology*; D001562:Benzimidazoles / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002191:Canrenoic Acid / Q000494:pharmacology; D019806:Cromakalim / Q000494:pharmacology; D005260:Female; D054086:KATP Channels / Q000037:antagonists & inhibitors; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D008901:Mineralocorticoids / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009543:Nifedipine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D024681:Potassium Channels, Calcium-Activated / Q000037:antagonists & inhibitors; D011189:Potassium Chloride / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D018161:Receptors, Mineralocorticoid / Q000502:physiology; D012084:Renin-Angiotensin System / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D054086:KATP Channels; D000451:Mineralocorticoid Receptor Antagonists; D008901:Mineralocorticoids; D024681:Potassium Channels, Calcium-Activated; D018161:Receptors, Mineralocorticoid; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D019806:Cromakalim; C086491:NS 1619; D010656:Phenylephrine; D000450:Aldosterone; D011189:Potassium Chloride; D002191:Canrenoic Acid; D009543:Nifedipine